Niraparib

• Capsules 100mg

Notes

1. NICE TA673: Niraparib (Zejula) is recommended for use within the Cancer Drugs Fund as an option for maintenance treatment for advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults (February 2021)
   1. It is recommended only if the conditions in the managed access agreement for niraparib are followed
2. NICE TA784: Niraparib (Zejula) is recommended as an option for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to the most recent course of platinum-based chemotherapy in adults (April 2022). It is recommended only if:
   1. they have a BRCA mutation and have had 2 courses of platinum-based chemotherapy, or
   2. they do not have a BRCA mutation and have had 2 or more courses of platinum-based chemotherapy, and
   3. the company provides it according to the commercial arrangement
3. MHRA Drug Safety Update (October 2020): Niraparib (Zejula): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment

Olaparib

• Tablets 100mg, 150mg

Notes

1. NICE TA598: Olaparib (Lynparza) is recommended for use within the Cancer Drugs Fund as an option for the maintenance treatment of BRCA mutation‑positive, advanced (FIGO stages 3 and 4), high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to first-line platinum-based chemotherapy in adults (August 2019). It is recommended only if the conditions in the managed access agreement for olaparib are followed.
2. NICE TA908: Olaparib (Lynparza) is recommended as an option for the maintenance treatment of relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults whose cancer has responded to platinum-based chemotherapy (July 2023), only if:
   1. they have a BRCA1 or BRCA2 mutation
      
   2. they have had 2 or more courses of platinum-based chemotherapy
      
   3. the company provides it according to the commercial arrangement.
      
3. NICE TA886: Olaparib (​Lynparza​) (alone or with endocrine therapy) ​is recommended​, within its marketing authorisation, as an option for the adjuvant treatment of HER2-negative high-risk early breast cancer that has been treated with neoadjuvant or adjuvant chemotherapy in adults with germline BRCA1 or 2 mutations, only if the company provides it according to the commercial arrangement (May 2023).
4. NICE TA887: Olaparib (Lynparza) is recommended, within its marketing authorisation, as an option for treating hormone-relapsed metastatic prostate cancer with BRCA1 or BRCA2 mutations that has progressed after a newer hormonal treatment (such as abiraterone or enzalutamide) in adults, only if the company provides it according to the commercial arrangement (October 2022).
5. NICE TA946: Olaparib (Lynparza) with bevacizumab (Avastin) is recommended, within its marketing authorisation, for maintenance treatment of high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults (January 2024) whose cancer:
   1. has completely or partially responded after first-line platinum-based chemotherapy with bevacizumab,
   2. is advanced (International Federation of Gynaecology and Obstetrics [FIGO] stages 3 and 4) and
   3. is homologous recombination deficiency (HRD) positive (defined as having either a BRCA1 or BRCA2 mutation, or genomic instability).
6. NICE TA951: Olaparib (Lynparza) with abiraterone and prednisone or prednisolone is recommended, within its marketing authorisation, as an option for untreated hormone-relapsed metastatic prostate cancer in adults who cannot have or do not want chemotherapy, only if the company provides it according to the commercial arrangements (February 2024).

Rucaparib

• Tablets 200mg, 250mg, 300mg

Notes

1. NICE TA611: Rucaparib (Rubraca) is recommended for use within the Cancer Drugs Fund as an option for maintenance treatment of relapsed platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults, only if the conditions in the managed access agreement for rucaparib are followed (November 2019)